Compare Cadila Healthcare with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs STRIDES PHARMA SCIENCE - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE STRIDES PHARMA SCIENCE CADILA HEALTHCARE/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 17.3 7.6 226.0% View Chart
P/BV x 2.3 0.9 252.5% View Chart
Dividend Yield % 1.5 0.5 281.1%  

Financials

 CADILA HEALTHCARE   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
CADILA HEALTHCARE/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs4321,147 37.7%   
Low Rs306642 47.7%   
Sales per share (Unadj.) Rs128.6317.2 40.5%  
Earnings per share (Unadj.) Rs18.57.8 236.4%  
Cash flow per share (Unadj.) Rs24.425.1 97.4%  
Dividends per share (Unadj.) Rs3.502.00 175.0%  
Dividend yield (eoy) %0.90.2 423.8%  
Book value per share (Unadj.) Rs101.5274.3 37.0%  
Shares outstanding (eoy) m1,023.7489.50 1,143.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.92.8 101.9%   
Avg P/E ratio x19.9114.0 17.5%  
P/CF ratio (eoy) x15.135.7 42.4%  
Price / Book Value ratio x3.63.3 111.6%  
Dividend payout %18.925.5 74.0%   
Avg Mkt Cap Rs m378,17080,058 472.4%   
No. of employees `00012.42.5 496.1%   
Total wages/salary Rs m21,2414,341 489.4%   
Avg. sales/employee Rs Th10,585.011,325.8 93.5%   
Avg. wages/employee Rs Th1,707.81,731.4 98.6%   
Avg. net profit/employee Rs Th1,526.5280.1 545.1%   
INCOME DATA
Net Sales Rs m131,65628,394 463.7%  
Other income Rs m2,011941 213.8%   
Total revenues Rs m133,66729,334 455.7%   
Gross profit Rs m29,7313,965 749.8%  
Depreciation Rs m5,9861,540 388.6%   
Interest Rs m1,9351,962 98.6%   
Profit before tax Rs m23,8211,403 1,697.6%   
Minority Interest Rs m4690-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m5,30397 5,450.2%   
Profit after tax Rs m18,987702 2,704.3%  
Gross profit margin %22.614.0 161.7%  
Effective tax rate %22.36.9 321.0%   
Net profit margin %14.42.5 583.2%  
BALANCE SHEET DATA
Current assets Rs m84,98124,836 342.2%   
Current liabilities Rs m73,42518,993 386.6%   
Net working cap to sales %8.820.6 42.7%  
Current ratio x1.21.3 88.5%  
Inventory Days Days7571 105.0%  
Debtors Days Days110113 96.6%  
Net fixed assets Rs m133,49334,289 389.3%   
Share capital Rs m1,024895 114.4%   
"Free" reserves Rs m102,83923,651 434.8%   
Net worth Rs m103,86324,546 423.1%   
Long term debt Rs m39,49715,513 254.6%   
Total assets Rs m234,83165,437 358.9%  
Interest coverage x13.31.7 776.1%   
Debt to equity ratio x0.40.6 60.2%  
Sales to assets ratio x0.60.4 129.2%   
Return on assets %8.94.1 218.8%  
Return on equity %18.32.9 639.1%  
Return on capital %18.36.9 265.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m48,40415,697 308.4%   
Fx outflow Rs m11,593735 1,576.4%   
Net fx Rs m36,81114,962 246.0%   
CASH FLOW
From Operations Rs m28,8231,871 1,540.8%  
From Investments Rs m-57,3875,826 -985.0%  
From Financial Activity Rs m18,846-10,157 -185.5%  
Net Cashflow Rs m-7,105-2,615 271.7%  

Share Holding

Indian Promoters % 74.8 27.7 270.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 37.8 22.0%  
FIIs % 5.9 8.6 68.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 25.9 42.5%  
Shareholders   44,069 56,241 78.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   GSK PHARMA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  AJANTA PHARMA  UNICHEM LAB  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Nov 15, 2019 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS